Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed Dose Study on the Efficacy of Lu AA21004 [Vortioxetine] on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder (MDD)

Trial Profile

Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed Dose Study on the Efficacy of Lu AA21004 [Vortioxetine] on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder (MDD)

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Vortioxetine (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms Cognition PoC; FOCUS
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 25 Oct 2016 Results of a post-hoc analysis assessing the effect of vortioxetine on cognitive functioning and depressive symptoms from 5 studies, published in the Journal of Clinical Psychiatry.
    • 26 May 2016 Results (post hoc analyses) assessing vortioxetine efficacy on cognitive dysfunction in depression published in the International Journal of Neuropsychopharmacology.
    • 04 Feb 2016 According to Lundbeck media release, FDA Psychopharmacologic Drug Advisory Committee supports the effectiveness of Brintellix and reviewed data from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top